Actively Recruiting
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Led by Fudan University · Updated on 2024-03-12
114
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
CONDITIONS
Official Title
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 20 and 80 years
- Diagnosed with primary adenocarcinoma of gastric cancer staged II or III by pathology
- Underwent R0 gastrectomy with D2 lymphadenectomy
- HER-2 positive confirmed by Immunohistochemistry or FISH
- ECOG performance status of 0 or 1 with expected survival over 6 months
- Normal blood counts, liver and kidney function, and electrocardiogram (WBC ≥3.5 x 10^9/L, NEU ≥1.2 x 10^9/L, PLT ≥90 x 10^9/L, HGB ≥80 g/L)
You will not qualify if you...
- Patients with stage I or IV gastric cancer
- Not eligible for R0 resection and D2 lymph node dissection
- Having multiple primary tumors
- Suffering from serious diseases such as cardiovascular, respiratory, kidney, or liver diseases, or poorly controlled hypertension, diabetes, or mental disorders
- History of chemotherapy, radiotherapy, immunotherapy, or targeted therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 2000000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here